Loading stock data…
RxSight (RXST)
$5.10-0.26 (-4.85%)
Market ClosedLast close Jun 29
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RxSight, Inc. in the Healthcare sector is trading at $5.10 with a market capitalization of $196M. Wall Street consensus targets $8.79 (7 analysts), implying a +72.3% move over the next 12 months. The stock is currently near its 52-week low of $4.48, remaining 38.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +72.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $30.89M↓ | $32.61M↑ | $30.34M↓ | $33.64M↓ | $37.90M |
| Gross Profit | $23.50M↓ | $25.26M↑ | $24.23M↓ | $25.19M↓ | $28.33M |
| Operating Income | -$17.83M↓ | -$11.34M↑ | -$12.18M↑ | -$14.00M↓ | -$10.67M |
| Net Income | -$15.88M↓ | -$9.15M↑ | -$9.82M↑ | -$11.79M↓ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$195.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.45%
Volume
Today's trading volume
4.75M
Recent News
National Vision and Smart Glasses: Early Investing Signals
EYE is pairing smart-glasses expansion, premium upgrades and military growth as it targets higher tickets and margin gains in 2026.
RxSight (RXST) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? Ronald Kurtz: Good afternoon, everyone, and thank you for joining us today. Before Mark takes us through the Q1 numbers, I'd like to provide an overview of our commercial progress, starting with the Annual Meeting of the American Society of Cataract and Refractive Surgery held just a few weeks ago in Washington, D.C. As the largest U.S. meeting focused on refractive and premium cataract surgery, RxSight's light adjustable lens technology continued to be a key focus for doctors.
RxSight, Inc. Q1 2026 Earnings Call Summary
Moby summary of RxSight, Inc.'s Q1 2026 earnings call
RxSight Q1 Earnings Call Highlights
RxSight (NASDAQ:RXST) executives said the company is seeing early signs that customer re-engagement efforts are helping stabilize utilization of its Light Adjustable Lens (LAL) platform, even as first-quarter revenue declined year over year due to lower sales of its Light Delivery Device (LDD) capit
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of -58.33% and +4.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?